范 瑜,李海萍

晚期复发性宫颈鳞癌（LSCC）是一种在宫颈癌患者中较为常见的疾病，特别是在经过治疗后仍然出现复发的病例。HE4（Human epididymis protein 4）是一种在上皮性肿瘤中表达较为特异的蛋白质，近年来被认为与多种恶性肿瘤的发生、发展及预后相关，尤其是在妇科肿瘤中，如卵巢癌、子宫内膜癌和宫颈癌。

宫颈癌；HE4

[1] 刘金阳,权丽丽.同步放化疗治疗复发性宫颈癌的疗效及安全性[J].癌症进展,2021,19(7):737-740. [2] 胡伯媛,许厚本,杨耀,等.实时超声弹性成像参数､血清CA153､IGF1及HE4水平与早期宫颈癌临床病理特征的关系及其预测价值分析[J].现代生物医学进展,2024,24(07):1335-1339. [3] Sung H,Ferlay J,Siegel RL,Laversanne M,Soerjomataram I,Jemal A,Bray F.Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin.2021 May;71(3):209-249. [4] Sung H,Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020:GLOBOCANEstimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin,2021,71(3):209-249. [5] Eduardo MG,Campaner AB,Silva MA.Apoptosis Phenomena in Squamous CellCarcinomas and Adenocarcinomas of the Uterine Cervix[J].Pathol Oncol Res,2015,21(4):887-892. [6] 唐双凤,林华明,黄逸生,等.信迪利单抗联合化疗治疗复发性宫颈癌的临床疗效和安全性研究[J].现代医学与健康研究电子杂志, 2024,8(18):61-63. [7] Siegel R L,Miller K D,Wagle N S,Jemal A.Cancer statistics,2023[J].CA:a cancer journal forclinicians,2023,73(1):17-48. [8] 张晓霞,田卫东,赵原原,等.2014⁃2019年武汉市居民宫颈癌死亡特征及潜在减寿年数[J].中华疾病控制杂志,2023,27(1):117-120. [9] 张韶凯,赵方辉,乔友林.中国宫颈癌防治研究20年历程与成就[J].中华流行病学杂志,2020,41(6):809-812. [10] 袁素云.宫颈癌筛查中应用高危型HPV联合液基薄层细胞检测的价值分析[J].中国社区医师,2017,33(35):123-124. [11] Abu-Rustum NR,Yashar CM,Bean S,et al.NCCN Guidelines Insights:CervicalCancer,Version 1.2020[J].J Natl Compr Canc Netw, 2020,18(6):660-666. [12] Small Jr W,Mell L K,Anderson P,Creutzberg C,De Los Santos J,Gaffney D,Jhingran A,Portelance L,Schefter T,Iyer R,Varia M,Winter K,Mundt A J.Consensus guidelines fordelineation of clinical target volume for intensity-modulated pelvic radiotherapy in postopera- tivetreatment of endometrial and cervical cancer[J].International Journal of Radiation Oncology*Biology* Physics, 2008, 71(2):428-434. [13] Wang W,Zhang F,Hu K,Hou X.Image-guided,intensity-modulated radiation therapy in definitiveradiotherapy for 1433 patients with cervical cancer[J].Gynecologic oncology,2018,151(3):444-448. [14] 朱贤海,黄健,耿建祥,等.我国区域性宫颈鳞癌患者中HPV感染型别和年龄分布[J].医学研究与战创伤救治,2024,37(08):824-829. [15] 苏兰芳,刘越雄,万江花,等.动态增强MRI与DWI在中老年宫颈癌分期诊断中的价值比较[J].中国老年学杂志,2022,42(7):1587-1590. [16] 高跃丽,耿欣,张静亚,等.MRI评估宫颈癌术前临床分期与病理诊断的一致性及预测预后的价值[J].临床误诊误治,2023,36(5):59-63. [17] 潘丹丹,吴磊,冯爱平.多层螺旋CT在宫颈癌FIGO分期及盆腔淋巴结转移诊断中的应用研究[J].中国临床医学影像杂志, 2024,35(05):347-350+359. [18] LALITKUMAR,V L BHARGAVA,SUNESHKUMAR,张力.晚期及复发宫颈鳞癌的化疗[J].癌症,1992,(03):200-203. [19] 洪文翠,吕银.局部晚期子宫颈癌放化疗后复发危险因素分析及列线图预测模型的构建[J].实用妇产科杂志,2023,39(4):302-307. [20] Oaknin A,Gladieff L,Martínez-García J,et al.VP5-2023:primary re-sults from BEATcc(ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG- 3030),a randomised phase III trial of first-line atezolizumab(atezo)combined with a platinum doublet and bevacizumab(bev)for meta-static (stage IVB),persistent or recurrent cervical cancer(R/M CC)[J].Ann Oncol,2023,34(12):1198-1200. [21] Judith V,Siebers A G,Bulten J,et al.Increasing incidence of invasive and in situcervical adenocarcinoma in the Netherlands during 2004-2013[J].Cancer Med,2017,6(2):416-423. [22] Zhao FJ,Su Q,Zhang W,Yang WC,Zhao L,Gao LY.Endu combined with concurrent chemotherapy and radiotherapy for stage IIB-IVA cervical squamous cell carcinoma patients.World J Clin Cases.2021 Sep 26;9(27):8061-8070. [23] 1BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics2018:GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in185countries[J].CA Cancer J Clin,2018,68(6):394-424. [24] DennyL.Cervical cancer treatment in Africa[J].Current Opinion inOncology,2011,23(5):469-474. [25] 张璐,朱园园,殷海涛.同步放化疗后程腔内放射治疗联合深部热疗治疗局部晚期宫颈癌的近期疗效观察[J].哈尔滨医科大学学报,2017,51(6):524-527. [26] 李仁河,邓清华,麦冰芳,等.贝伐单抗联合TP化疗方案对复发性宫颈癌患者血清肿瘤标志物及生存周期的影响〔J〕.广东医科大学学报,2020,38(3):358-360. [27] 刘龑昊,王俊杰.复发宫颈癌近距离治疗进展[J].中华放射肿瘤学杂志,2021,30(3):297-300. [28] 李英,程忠平.复发性宫颈癌免疫治疗的研究进展[J].中国妇产科临床杂志,2023,24(1):108-110. [29] 巨宇叶,张芳芳,王晓慧.复发性宫颈癌的治疗现状及进展〔J〕.国际妇产科学杂志,2021,48(1):56-70. [30] Li J,Dowdy S,Tipton T,et al.HE4 as a biomarker for ovarian and endometrial cancer management[J].ExpertRev Mol Diagn,2009,9(6)∶555-566. [31] HanLN,HanYW,YanP.Prognosticvaluesofhumanepi-didymisprotein4expressioninpatientswithendometrialcancer:Asystematicreviewan- dmeta-analysis[J].JObstetGynaecolRes,2022,48(9):2255-2269. [32] 林海良,宋西明.替雷利珠单抗联合多西他赛对宫颈癌的免疫功能､中性粒细胞/淋巴细胞比值(NLR)､IFN-γ以及HE4､CA125､SCCA､AFP表达水平的影响[J].黑龙江医药,2024,37(02):359-362. [33] DubeyH,RanjanA,DuraiJ,etal.EvaluationofHE4asaprognosticbiomarkerinuterinecervicalcancer[J].CancerTreatResCommun,2023,34:100672. [34] Guo M,Liang L,Wu L,etal. Application value of real-timeultrasonic elastograph with serum human epididymis protein4, interleukin-33, and carbohydrate antigen 153 in diagnosisof early cervical cancer [J].J Healthc Eng,2022,2022:4880874. [35] 钟思意,林小文,刘嘉欣,王如意,梁涛,邓峥峰,钟傲,韩翠平.荧光磁性碳点对卵巢癌细胞的靶向成像与检测[J].无机化学学报, 2024, 40(08):1483-1490. [36] 巨宇叶,张芳芳,王晓慧.复发性宫颈癌的治疗现状及进展[J].国际妇产科学杂志,2021,48(1):56-70. [37] 薛慧莹,孟芳,易利霞.血清SCC-Ag､HE4､SMAD4水平与宫颈癌放化疗敏感性的相关性分析[J].实用癌症杂志,2024,39(05):745-748. [38] 陈珊珊,杨睿,肖涛,等.血清肿瘤标志物水平在宫颈癌病情监测及预后评估中的价值[J].中国肿瘤临床与康复,2022,29(8):965-968. [39] HwangWY,SuhDH,KimK,etal.Serumhumanepididy-misprotein4asaprognosticmarkerincervicalcancer[J].CancerControl,2022,29:1073274822109 7778.

点击下载PDF